Wolfe Research Maintains Outperform on Netflix, Raises Price Target to $706

Wolfe Research analyst John Janedis maintains Netflix (NASDAQ:NFLX) with a Outperform and raises the price target from $625 to $706.

byBenzinga Newsdesk

October 20, 2021

1 minute read

Wolfe Research analyst John Janedis maintains Netflix (NASDAQ:NFLX) with a Outperform and raises the price target from $625 to $706.

Wipro And Informatica Partner To Bring Cloud-Based Data And Analytics To Market With Wipro Fullstride Cloud Services Data Platform

By Benzinga Newsdesk

Today, 5:37 PM

https://www.wipro.com/newsroom/press-releases/2022/wipro-and-informatica-partner-to-bring-cloud-based-data-and-analytics-to-market-with-wipro-fullstride-cloud-services-data-platform/ Wipro Limited (NYSE:WIT,

WIT

Archaea Signs 5-Year Renewable Natural Gas Agreement With UGI Utilities, Inc.; Financial Terms Not Disclosed

By Bill Haddad

Today, 5:37 PM

Contract to deliver over 300,000 MMBtu per year of RNG HOUSTON--(BUSINESS WIRE)-- Archaea Energy Inc. (“Archaea”) (NYSE:LFG), an industry leading renewable natural gas (“RNG”) company, announced

LFG

Deutsche Bank Maintains Hold on Domino’s Pizza, Lowers Price Target to $468

By Benzinga Newsdesk

Today, 5:37 PM

Deutsche Bank analyst Brian Mullan maintains Domino's Pizza (NYSE:DPZ) with a Hold and lowers the price target from $485 to $468.

DPZ

Philips’ Ventilator Woes Continue With Another FDA Class I Recall

By Vandana Singh

Today, 5:38 PM

Koninklijke Philips NV's (NYSE: PHG) Respironics is recalling Certain V60 and V60 Plus ventilators because a subset of these devices had parts put together using an expired adhesive.

PHG

Wolfe Research Maintains Outperform on Netflix, Raises Price Target to $706

Related Posts

Wipro And Informatica Partner To Bring Cloud-Based Data And Analytics To Market With Wipro Fullstride Cloud Services Data Platform

Archaea Signs 5-Year Renewable Natural Gas Agreement With UGI Utilities, Inc.; Financial Terms Not Disclosed

Deutsche Bank Maintains Hold on Domino’s Pizza, Lowers Price Target to $468

Philips’ Ventilator Woes Continue With Another FDA Class I Recall